The Predictive Value of Serum Erythropoietin Levels Measured at Diagnosis in Patients With Myelodysplastic Syndromes.

Fiche publication

Date publication

août 2026

Journal

EJHaem

Auteurs

Membres identifiés du Cancéropôle Est :
Dr D'AVENI-PINEY Maud

Tous les auteurs :
Culligan D, Taylor A, Smith A, Cargo C, Oster H, Symeonidis A, Stauder R, Langemeijer S, Malcovati L, Fenaux P, Čermák J, Hellström-Lindberg E, Mills J, Kotsianidis I, D'Aveni M, van Marrewijk C, Hoeks M, de Witte T, Bowen D, Mittelman M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42529759

Résumé

: To study the predictive and prognostic values of serum erythropoietin levels (sEPO) measured at diagnosis in lower-risk myelodysplastic syndromes. : We analyzed clinical associations and prognosis with sEPO in 672/1610 patients with at least one year of follow-up data in the prospective EUMDS study. : sEPO levels increase with WHO subtypes associated with erythroid hypoplasia and poorer risk IPSS-R scores. sEPO is an independent predictor of transfusion free survival and levels < 200 IU/L predict response to ESA. sEPO is not an independent predictor of overall survival. : sEPO predicts transfusion free survival and response to ESA. : The EUMDS Registry (ClinicalTrials.gov: Identifier NCT00600860).